Actbtm3(Kras*)Arge
Targeted Allele Detail
|
Symbol: |
Actbtm3(Kras*)Arge |
Name: |
actin, beta; targeted mutation 3, Argiris Efstratiadis |
MGI ID: |
MGI:7388568 |
Synonyms: |
KRAS*A |
Gene: |
Actb Location: Chr5:142888870-142892509 bp, - strand Genetic Position: Chr5, 81.8 cM
|
Alliance: |
Actbtm3(Kras*)Arge page
|
|
|
Allele Type: |
|
Targeted (Conditional ready, Constitutively active, Inserted expressed sequence) |
Mutation: |
|
Insertion
|
|
|
Actbtm3(Kras*)Arge expresses
1 gene
Knock-in expresses:
Organism |
Expressed Gene |
Note |
mouse |
Kras (MGI:96680) |
Contains G12D mutation. |
|
|
|
Mutation details: An IRES and loxP site flanked neomycin resistance gene and STOP cassette were inserted along with a constitutively active Kras cDNA with the amino acid substitution of glycine with aspartic acid at position 12 (p.G12D) into intron 1. Cre-mediated removal of the STOP cassette is required to achieve expression of the constitutively active Kras.
(J:217168)
|
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
Carrying any Actb Mutation: |
52 strains or lines available
|
|
Original: |
J:217168 Stellas D, et al., Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst. 2014 Dec;106(12) |
All: |
1 reference(s) |
|